의약품 허가-특허 연계제도의 등재의약품에 대한특허 도전에 관한 연구

키워드

참고문헌 (41)

1. 김대중, "의약품 허가특허연계에서 제네릭 시장독점제도에 관한 연구", 보건경제와 정책연구, 19(1), pp.55~76 (2013)
2. 박실비아, "미국과 캐나다의 의약품 허가-특허 연계제도", 약제학회지, 38(3), pp.207~215 (2008)
3. 식품의약품안전처, "의약품 허가특허연계제도 해설서", 식품의약품안전처, ~ (2018)
4. 신혜은, "우리나라 제약산업 실정에 부합하는 한국형 허가-특허연계제도의 시행방안", 안암법학, (43), pp.1083~1118 (2014)
5. 오인선, "의약품 허가-특허연계제도에 관한 연구", 박사, pp.2021
6. 정용익, "한국의 의약품 허가-특허연계제도에서 제네릭 시장독점 제도의 도입 필요성에 관한 연구", 지식재산연구, 9(4), pp.101~129 (2014)
7. 제약분야의 에버그린 특허전략과 분쟁 사례 연구, "정윤택", 한국보건산업진흥원, ~ (2009)
8. 주시형, "기술혁신 보호전략에 대한 연구-한국기업의 제품혁신을 중심으로", 한국혁신학회지, 7(1), pp.3~28 (2012)
9. Arora, A, M. Ceccagnoli, "R&D and the Patent Premium", International Journal of Industrial Organization, 26(5), pp.1153~1179 (2008)
10. Bulow, J., "Innovation Policy and the Economy", pp.145~187 (2004), MIT Press
11. Protecting their intellectual assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not), "Cohen, W", NBER, ~, pp.NBER Working Paper, 7552 (2000)
12. Derzko, N. M., "The Impact of Recent Reforms of the Hatch-Waxman Scheme on Orange Book Strategic Behavior and Pharmaceutical Innovation", The Journal of Law and Technology, 45(2), pp.165~265 (2004)
13. Engelberg, A., "Balancing innovation, access, and profits-market exclusivity for biologics", The New England Journal of Medicine, 361, pp.1917~1919 (2009)
14. Engelberg, A. B., "Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness?", Journal of Law and Technology, 39, pp.389~426 (1999)
15. Fine, J. P., "A proportional hazards model for the subdistribution of a competing risk", Journal of the American Statistical Association, 94, pp.496~509 (1999)
16. Grabowski, H., "Are the economics of pharmaceutical R&D changing : productivity, patents, and political pressure", PharmacoEconomics, 22, pp.15~24 (2004)
17. Grabowski, H., "Updated trends in US brand-name and generic durg competition", Journal of Medical Economics, 19(9), pp.836~844 (2016)
18. Grabowski, H., "Continuing trends in U. S. brand-name and generic drug competition", Journal of Medical Economics, 24(1), pp.908~917 (2021)
19. Grabowski, H. G., "Generic Competition and Market Exclusivity Periods in Pharmaceuticals", Managerial and Decision Economics, 28, pp.491~502 (2007)
20. Grabowski, H. G., "Recent trends in brand-name and generic drug competition", Journal of Medical Economics, 17(3), pp.207~214 (2014)
21. Grabowski, H. G., "Evolving Brand-Name and Generic Drug Competition May Warrant A Revision of the Hatch-Waxman Act", Health Affairs, 30(11), pp.2157~2166 (2011)
22. Harhoff, D., "Citations, family size, opposition and the value of patent rights", Research Policy, 32, pp.1343~1363 (2003)
23. Hemphill, C. S., "When Do Generic Challenge Drug Patents?", Journal of Empirical Legal Studies, 8(4), pp.613~649 (2011)
24. Hemphill, C. S., "Evergreening, patent challenges, and effect market life in pharmaceuticals", Journal of Health Economics, 31, pp.327~339 (2012)
25. Higgins, M, "Balancing innovation and access : patent challenges tip the scales", Science, 326, pp.370~371 (2009)
26. Kesselheim, A., "Biomedical patents and the public’s health : is there a role for eminent domain?", Journal of the American Medical Association, 295, pp.434~437 (2006)
27. Lanjouw, J., "Patent Quality and Research Productivity : Measuring Innovation with Multiple Indicators", The Economic Journal, 114(495), pp.441~465 (2004)
28. Lerner, J., "The Importance of Patent Scope : An Empirical Analysis", RAND Journal of Economics, 25(2), pp.319~333 (1994)
29. Levin R, "Appropriating the returns from industrial research and development", Brookings Papers on Economic Activity, 1987(3), pp.783~832 (1987)
30. Manh, T. G., "Patenting Drug Products : Anticipating Hatch-Waxman Issues During the Claims Drafting Process", Food and Drug Law Journal, 54(2), pp.245~253 (1999)
31. Sakakibara M., "Do stronger patents induce more innovation? evidence from 1988Japanese patent law reforms", RAND Journal of Economics, 32(1), pp.77~100 (2001)
32. Schankerman, M., "How Valuable is Patent Protection? Estimates by Technology Field", The RAND Journal of Economics, 29(1), pp.77~107 (1998)
33. Schuster, N. A., "Ignoring competing events in the analysis of survival data may lead to biased results : a nonmathematical illustration of competing risk analysis", Journal of Clinical Epidemiology, 122, pp.42~48 (2020)
34. Son, K., "Patenting and patent challenges in South Korea after introducing a patent linkage system", Globalization and Health, 18, pp.95~ (2022)
35. Son, K., "Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?", Frontiers in Public Health, 11, pp.1120729~ (2023)
36. Son, K., "Patent challenges and factors associated with successful patent challengers under the patent linkage system : recent evidence from South Korea after the Korea United States free trade agreement", Globalization and Health, 17, pp.116~ (2021)
37. Son, K., "Does the Patent Linkage System Prolong Effective Market Excusivity? Recent Evidence From the Korea-U. S. Free Trade Agreement in Korea", International Journal of Social Determinants of Health and Health Services, 49(2), pp.306~321 (2019)
38. Sterzi, V., "Patent quality and ownership : An analysis of UK faculty patenting", Research Policy, 42(2), pp.564~576 (2013)
39. Tong X., "Measuring national technological performance with patent claim data", Research Policy, 23(2), pp.133~141 (1994)
40. Tu, S. S., "What Litigators Can Teach the Patent Office about Pharmaceutical Patents", Wasington University Law Review, 99(5), pp.1673~1731 (2022)
41. US Congressional Budge Office, "How Increased Competition Has Affected Price and Returns in the Pharmaceutical Industry", ~ (1998)

관련 논문AI추천